Management of superficial and muscle-invasive urothelial cancers of the bladder

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 281-288

  Resnick, Matthew J ^a,b   Bassett, Jeffrey C ^a   Clark, Peter E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

bladder cancer; cystectomy; management; review

Indexed keywords

BCG VACCINE; CISPLATIN; DOCETAXEL; METHOTREXATE; MITOMYCIN; PACLITAXEL; VINBLASTINE;

BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MULTIPLE CANCER; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; TRANSURETHRAL RESECTION; TUMOR VOLUME;

HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 84876298276     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835eb583     Document Type: Review

References (74)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Cooksley CD, Avritscher EBC, Grossman HB, et al. Clinical model of cost of bladder cancer in the elderly. Urology 2008; 71:519-525.
3. Revelo MP, Cookson MS, Chang SS, et al. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol 2004; 171 (2 Pt 1):646-651.
4. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992; 19:429-433.
5. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:2314-2330.
6. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130:1083-1086.
7. Kiemeney LA, Witjes JA, Heijbroek RP, et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150:60-64.
8. Holmäng S, Hedelin H, Anderström C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153:1823-1826.
9. Millán-Rodŕiguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163:73-78.
10. Kamat AM, Dinney CPN, Gee JR, et al. Micropapillary bladdercancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007; 110:62-67.
11. Kamat AM, Gee JR, Dinney CPN, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006; 175 (3 Pt 1):881-885.
12. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-475.
13. Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009; 56:903-910.
14. Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171 (6 Pt 1):2186-2190.
15. Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970.
16. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67:1216-1223.
17. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001; 88:209-216.
18. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 90-95.
19. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163:1124-1129.
20. Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for nonmuscle-invasive bladder cancer. Eur Urol 2009; 56:247-256.
21. Sylvester RJ, van der Meijden APM, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174: 86-91.
22. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guerin in inter mediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013; 63:442-462.
23. Di Lorenzo G, Perdona S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in nonmuscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010; 116:1893-1900.
24. Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010; 28:543-548.
25. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel in the management of recurrent nonmuscle-invasive bladder cancer (NMIBC) after previous BCG therapy. J Urol 2012. [Epub ahead of print].
26. Lammers RJM, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of nonmuscle-invasive bladder cancer: a systematic review. Eur Urol 2011; 60:81-93.
27. Bassett JC, Gore JL, Chi AC, et al. Impact of a bladder cancer diagnosis on smoking behavior. J Clin Oncol 2012; 30:1871-1878.
28. Bjurlin MA, Cohn MR, Kim DY, et al. Brief smoking cessation intervention: a prospective trial in the urology setting. J Urol 2012. [Epub ahead of print].
29. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328:1519.
30. Dresler CM, Leon ME, Straif K, et al. Reversal of risk upon quitting smoking. Lancet 2006; 368:348-349.
31. Chen C-H, Shun C-T, Huang K-H, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 2007; 100:281-286.
32. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 1999; 86:2337-2345.
33. Rink M, Furberg H, Zabor EC, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary nonmuscle-invasive bladder cancer. Eur Urol 2012 [Epub ahead of print].
34. Rink M, Xylinas E, Babjuk M, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol 2012; 188:2120-2128.
35. Lammers RJM, Witjes WPJ, Hendricksen K, et al. Smoking status is a risk factor for recurrence after transurethral resection of nonmuscle-invasive bladder cancer. Eur Urol 2011; 60:713-720.
36. Chamie K, Saigal CS, Lai J, et al. Quality of care in patients with bladder cancer: a case report? Cancer 2012; 118:1412-1421.
37. Schrag D, Hsieh LJ, Rabbani F, et al. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003; 95:588-597.
38. Madeb R, Golijanin D, Noyes K, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 2009; 115:2660-2670.
39. Huang GJ, Hamilton AS, Lo M, et al. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol 2008; 180:520-524.
40. Burks FN, Liu AB, Suh RS, et al. Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. J Urol 2012; 188:2108-2113.
41. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol 2001; 19:666-675.
42. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51:137-149.
43. Mitra AP, Skinner EC, Miranda G, Daneshmand S. A precystectomy decision model to predict pathological upstaging and oncological out comes in clinical stage T2 bladder cancer. BJU Int 2013; 111:240-248.
44. Green DA, Rink M, Hansen J, et al. Accurate preoperative prediction of nonorgan-confined bladder urothelial carcinoma at cystectomy. BJU Int 2012. [Epub ahead of print].
45. International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24:3967-3972.
46. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006; 50:1254-1260.
47. Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 2005; 65:1118-1125.
48. Gore JL, Litwin MS, Lai J, et al. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst 2010; 102:802-811.
49. Gore JL, Wright JL, Daratha KB, et al. Hospital-level variation in the quality of urologic cancer surgery. Cancer 2012; 118:987-996.
50. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol 2005; 173:1318-1322.
51. Stein JP. The role of lymphadenectomy in patients undergoing radical cystectomy for bladder cancer. Curr Oncol Rep 2007; 9:213-221.
52. Dorin RP, Daneshmand S, Eisenberg MS, et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur Urol 2011; 60:946-952.
53. Morgan TM, Kaffenberger SD, Cookson MS. Surgical and chemotherapeutic management of regional lymph nodes in bladder cancer. J Urol 2012; 188:1081-1088.
54. Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphade-nectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. JURO 2004; 171:139-144.
55. Bruins HM, Dorin RP, Rubino B, et al. Critical evaluation of the American Joint Committee on Cancer TNM nodal staging system in patients with lymph node-positive disease after radical cystectomy. Eur Urol 2012; 62:671-676.
56. Zehnder P, Studer UE, Skinner EC, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 2011; 186:1261-1268.
57. Abol-Enein H, Tilki D, Mosbah A, et al. Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol 2011; 60:572-577.
58. Challacombe BJ, Bochner BH, Dasgupta P, et al. The roleof laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol 2011; 60:767-775.
59. Pruthi RS, Nielsen ME, Nix J, et al. Robotic radical cystectomy for bladder cancer: surgical and pathological outcomes in 100 consecutive cases. J Urol 2010; 183:510-514.
60. Wang GJ, Barocas DA, Raman JD, Scherr DS. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int 2008; 101:89-93.
61. Hellenthal NJ, Hussain A, Andrews PE, et al. Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystect-omy Consortium. J Urol 2010; 184:87-91.
62. Wang GJ, Barocas DA, Raman JD, Scherr DS. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int 2008; 101: 89-93.
63. Kauffman EC, Ng CK, Lee MM, et al. Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy. BJU Int 2011; 107:628-635.
64. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205-213.
65. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55:164-174.
66. Nix J, Smith A, Kurpad R, et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 2010; 57:196-201.
67. Ng CK, Kauffman EC, Lee MM, et al. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 2010; 57:274-281.
68. Khan MS, Elhage O, Challacombe B, et al. Analysis of early complications of robotic-assisted radical cystectomy using a standardized reporting system. Urology 2011; 77:357-362.
69. Guru KA, Kim HL, Piacente PM, Mohler JL. Robot-assisted radical cystectomy and pelvic lymph node dissection: initial experience at Roswell Park Cancer Institute. Urology 2007; 69:469-474.
70. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder;Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vin-blastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29:2171-2177.
71. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866.
72. Keegan KA, Resnick MJ, Clark PE. Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. Curr Opin Oncol 2012; 24:278-283.
73. Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J Urol 2006; 24:531-542.
74. Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62:523-533.